The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK.
SARS-COV-2
Virus evolution
Within-host evolution
variants of concern
Journal
Virus evolution
ISSN: 2057-1577
Titre abrégé: Virus Evol
Pays: England
ID NLM: 101664675
Informations de publication
Date de publication:
2022
2022
Historique:
received:
23
03
2022
revised:
28
07
2022
accepted:
25
08
2022
entrez:
19
12
2022
pubmed:
20
12
2022
medline:
20
12
2022
Statut:
epublish
Résumé
The first SARS-CoV-2 variant of concern (VOC) to be designated was lineage B.1.1.7, later labelled by the World Health Organization as Alpha. Originating in early autumn but discovered in December 2020, it spread rapidly and caused large waves of infections worldwide. The Alpha variant is notable for being defined by a long ancestral phylogenetic branch with an increased evolutionary rate, along which only two sequences have been sampled. Alpha genomes comprise a well-supported monophyletic clade within which the evolutionary rate is typical of SARS-CoV-2. The Alpha epidemic continued to grow despite the continued restrictions on social mixing across the UK and the imposition of new restrictions, in particular, the English national lockdown in November 2020. While these interventions succeeded in reducing the absolute number of cases, the impact of these non-pharmaceutical interventions was predominantly to drive the decline of the SARS-CoV-2 lineages that preceded Alpha. We investigate the only two sampled sequences that fall on the branch ancestral to Alpha. We find that one is likely to be a true intermediate sequence, providing information about the order of mutational events that led to Alpha. We explore alternate hypotheses that can explain how Alpha acquired a large number of mutations yet remained largely unobserved in a region of high genomic surveillance: an under-sampled geographical location, a non-human animal population, or a chronically infected individual. We conclude that the latter provides the best explanation of the observed behaviour and dynamics of the variant, although the individual need not be immunocompromised, as persistently infected immunocompetent hosts also display a higher within-host rate of evolution. Finally, we compare the ancestral branches and mutation profiles of other VOCs and find that Delta appears to be an outlier both in terms of the genomic locations of its defining mutations and a lack of the rapid evolutionary rate on its ancestral branch. As new variants, such as Omicron, continue to evolve (potentially through similar mechanisms), it remains important to investigate the origins of other variants to identify ways to potentially disrupt their evolution and emergence.
Identifiants
pubmed: 36533153
doi: 10.1093/ve/veac080
pii: veac080
pmc: PMC9752794
doi:
Types de publication
Journal Article
Langues
eng
Pagination
veac080Subventions
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M010996/1
Pays : United Kingdom
Organisme : European Research Council
ID : 725422
Pays : International
Organisme : Medical Research Council
ID : MR/W005611/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19026
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
Lancet Microbe. 2020 Jul;1(3):e99-e100
pubmed: 32835336
Virus Evol. 2018 Jan 08;4(1):vex042
pubmed: 29340210
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Virus Evol. 2021 Dec 15;7(2):veab091
pubmed: 35039782
Science. 2021 May 21;372(6544):815-821
pubmed: 33853970
J Autoimmun. 2021 Nov;124:102715
pubmed: 34399188
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
Nature. 2021 May;593(7857):136-141
pubmed: 33706364
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):
pubmed: 34732584
Cell. 2021 Sep 30;184(20):5179-5188.e8
pubmed: 34499854
J Mol Evol. 1985;22(2):160-74
pubmed: 3934395
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Syst Biol. 2018 Sep 1;67(5):901-904
pubmed: 29718447
Nature. 2022 Feb;602(7896):294-299
pubmed: 34818667
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Lancet. 2022 Mar 12;399(10329):1070-1078
pubmed: 35279259
Nature. 2015 Oct 1;526(7571):122-5
pubmed: 26416728
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5
pubmed: 35120605
Cell. 2021 May 13;184(10):2605-2617.e18
pubmed: 33831372
Emerg Infect Dis. 2021 Apr;27(4):
pubmed: 33567247
Nature. 2022 Oct;610(7930):154-160
pubmed: 35952712
Nature. 2022 Mar;603(7902):706-714
pubmed: 35104837
Nat Commun. 2021 Nov 4;12(1):6405
pubmed: 34737266
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34417349
Mol Biol Evol. 2013 Mar;30(3):713-24
pubmed: 23180580
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553059
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Nature. 2021 Jul;595(7869):707-712
pubmed: 34098568
Clin Infect Dis. 2022 Jul 06;:
pubmed: 35793242
Science. 2004 Jan 16;303(5656):327-32
pubmed: 14726583
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Cell Rep. 2021 Jun 29;35(13):109292
pubmed: 34166617
Vaccines (Basel). 2021 Mar 19;9(3):
pubmed: 33808687
J Infect. 2020 Jul;81(1):e24-e27
pubmed: 32283146
Elife. 2021 Aug 20;10:
pubmed: 34414884
Science. 2020 Sep 25;369(6511):1603-1607
pubmed: 32732280
Mol Biol Evol. 2001 Jun;18(6):1001-13
pubmed: 11371589
Nat Microbiol. 2021 Jul;6(7):899-909
pubmed: 33907312
Nat Commun. 2020 Feb 7;11(1):766
pubmed: 32034144
Nat Microbiol. 2021 Jul;6(7):821-823
pubmed: 34108654
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Nature. 2021 May;593(7859):321-322
pubmed: 33976409
Mol Biol Evol. 2019 Jul 31;:
pubmed: 31364710
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):228-33
pubmed: 23248286
PLoS Pathog. 2021 Nov 12;17(11):e1009952
pubmed: 34767598
Mol Biol Evol. 2020 May 1;37(5):1530-1534
pubmed: 32011700
Nat Med. 2021 Jul;27(7):1230-1238
pubmed: 34035535
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Cell Rep Med. 2021 Apr 20;2(4):100255
pubmed: 33842902
Cell Mol Immunol. 2022 Feb;19(2):293-295
pubmed: 35017716
Microbiol Spectr. 2022 Feb 23;10(1):e0236621
pubmed: 35196783
Science. 2021 Aug 20;373(6557):889-895
pubmed: 34301854
Science. 2021 Apr 16;372(6539):
pubmed: 33688063
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Nat Commun. 2021 Nov 23;12(1):6802
pubmed: 34815406
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
Science. 2021 Mar 12;371(6534):1139-1142
pubmed: 33536258
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Nat Commun. 2021 Feb 8;12(1):848
pubmed: 33558493